MDR treatment. Shanghai, May 2012 Arnaud Trébucq The Union
|
|
- Raymond Stevenson
- 5 years ago
- Views:
Transcription
1 MDR treatment Shanghai, May 2012 Arnaud Trébucq The Union
2 Why to diagnose MDR-TB?
3 Outcome of SS+ new MDR-TB cases, treated with First Line TB (FLD) drugs Setting Success Died Fail LFFU Transf. Corea 20(56) 1(3) 11(31) 0 4(11) Peru 14(58) 4(17) 6(25) 0 0 Hong Kong 42(60) 6(9) 3(4) 5(7) 14(20) Ivanovo Obl. 2(11) 4(22) 8(44) 3(17) 1(6) Dominic R 10(53) 1(5) 3(16) 4(21) 1(5) Italy 7(41) 0 8(47) 2(12) 0 Total 95(52) 16(9) 39(21) 14(7) 20(11) Espinal MA et al. JAMA 2000;283(19):
4 Is the cure rate with FLD true? Heilongjiang province, China 241 MDR cases: 179 (74%) cured with FLD 4 years later, among the cured, 101 were retrieved, 54% relapsed! Need for other treatment than First line drugs He GX et al. Follow-Up of Patients with Multidrug Resistant Tuberculosis Four Years after Standardized First-Line Drug Treatment. PLoS ONE 2010;5(5):e10799
5 Available TB drugs 1 st group : First line oral drugs Pyrazinamide (Z), Ethambutol (E), Isoniazid (H)?? 2 nd group : injectable Kanamycin (Km), Amikacin (Am), Viomycin (Vio), Capreomycin (Cm) 3 rd group : fluoroquinolones Ciprofloxacin (Cfx), Ofloxacin (Ofx), Levofloxacin (Lfx), Gatifloxacin (Gfx), Moxifloxacin (Mfx) 4 th group: oral bacteriostatic second line drugs Thioamides: Ethionamide (Eto) et Prothionamide (Pto), PAS, Cycloserine (Cs) 5 th group: Drugs with unclear efficacy Clofazimine (Cfz), Amoxicillin/clavulanate (Amx/Clv), Clarithromycin (Clr), Linezolid (Lzd)
6 Treatment outcomes, individualised MDR-TB treatments
7 Treatment outcomes, standardised versus individualised regimens for MDR-TB
8 Treatment outcomes for MDR-TB, new cases versus previously treated. GLC, Estonia, Latvia, Lima Nathanson et al.emerging Infectious Diseases 2006 (12);9;
9 Time for sputum culture to convert, Latvia 2000 (Individualised treatments) TH Holtz et al. Ann Intern Med. 2006;144:
10 Which treatment for MDR-TB? Individualised or standardised treatment? Which drugs? How many drugs? Which combination? Which length for intensive phase? Which length for continuation phase? Hospitalisation or ambulatory?
11 Basis of short-course chemotherapy Susceptible bacilli populations Active growth Cavities: >10 9 Intermittent growth Macrophages 10 5 A B INH Streptomycin Rifampicin Rifampicin INH Slow growth (Acid) 10 3 Dormant C Pyrazinamid (Ph acid) Rifampicin Adaptation from D. Mitchison and JM Dickinson Bull Int Un Tub 53,4, 1978 What could we have for MDR bacilli?
12 Some key elements on fluoroquinolones First quinolone generation: nalidixic acid Second-generation Ex. ciprofloxacin and ofloxacin Third-generation Ex. sparfloxacin and levofloxacin Fourth-generation Ex. gatifloxacin and moxifloxacin
13 Early Bactericidal Activity of new fluoroquinolones (40 TPM+) Johnson JL,Int.J.Tuberc.Lung Dis. 10 (2006): Conclusion: 3 rd and 4 th generation of FQL as good as INH
14 Comparative early bactericidal activity (EBA*) of isoniazid and moxifloxacin Authors Place of study For day Isoniazid 300mg/day Moxifloxacin 400mg/day Pletz et al, 2004** Gillepsie et al., 2005 Germany Tanzania Johnson et al., 2006 Brazil * Decline in log 10 CFU /ml of sputum per day ** Dosing of isoniazid was 6mg/kg
15 Comparative activities of fluoroquinolones against M. tuberculosis in mice Controls (From Ji et al., AAC 1995; 39: ) Conclusion: levofloxacin is more active than ofloxacin at equal dose.
16 Comparative activities of isoniazid (INH), sparfloxacin (Spar) and moxifloxacin (Moxi) against M. tuberculosis in mice (From Ji et al., AAC 1998; 42: ) Conclusion: the bactericidal activity of moxifloxacin is close to that of isoniazid
17 Comparative activity of oflo, levo and moxi in combination with second line drugs in TB infected mice Drug Regimen Untreated 7.86±0.25 Log 10 CFU counts in mouse lungs, different time points 0 Month 2 Month 6 Month 9 Month 12 2RHZ/4RH 3.21±0.54 < OEZA/10OE 3.45± ± ± ± LEZA/10LE 3.38± ± ± MEZA/10ME 1.82±0.39 <0.07 <0.07 <0.07 O, ofloxacin, 200mg/kg; L, levofloxacin, 200mg/kg; M, moxifloxacin, 100mg/ kg; E, Ethionamide, 50mg/kg; A, amikacin, 150mg/kg Conclusion: Moxifloxacin 100 (M) > Levofloxacin 200 (L) > Ofloxacin 200 (O) during the initial and continuation phases * Veziris & al. Antimicrobial agents and chemotherapy 2003: 47:
18 Rustomjee & al. Sterilising activities of O, G and M in pulm TB. IJTLD 2008:12: ) Compara.ve bactericidal ac.vi.es of RHZE, RHZO, RHZG, & RHZM (S.S.C.C.) in pa.ents GaK GaK & Moxi Moxi SSCC= serial sputum CFU counts; R=rifampicin; H= isoniazid; Z= pyrazinamide; E= ethambutol; O= ofloxacin; G, gatifloxacin; M, moxifloxacin
19 Sterilising activity of moxifloxacin In vitro studies In vitro, selection M. tuberculosis persisters with some rifampicin by killing fast growing bacilli. Exposition of these selected bacilli to INH, or ofloxacin or levofloxacin or moxifloxacin Much better destruction of bacilli with moxifloxacin and gatifloxacin than with INH or ofloxacin Hu, Y., A. R. M. Coates, and D. A. Mitchison. "Sterilizing activities of fluoroquinolones against rifampin-tolerant populations of Mycobacterium tuberculosis." Antimicrob.Agents Chemother. 47 (2003):
20 Viable counts for 100-day cultures of M. t exposed first to rifampin and then to various concentrations of fluoroquinolones
21 Pharmacodynamic values as a guide to antibiotic decision making* The area under the concentration curve (AUC) and the M.I.C. dictate the antimicrobial response. For «optimal» antimicrobial effect against rapidly growing organisms, it has been proposed: C max / MIC 90 should be >10 AUC 24 / MIC 90 (AUIC) should be >125 (best >250) * From Craig, CID. 1998; 26: 1-12; Wright et al., JAC 2000; 46: ; Schentag et al., CID 2001; 32 (Suppl 1): S39-46; MacGowan et al., CID 2001; 33 (Suppl 3): S214- S220.
22 Pharmacodynamic values of fluoroquinolones against M. tuberculosis* Drug (-floxacin) MIC 90 C max /MIC 90 AUC 24 /MIC 90 Cipro O Levo Spar Moxi Gati * From Hooper et Wolfson AAC 1985 ; 28 : ; Hooper, Clin. Inf. Dis ; 30 : ; Lubasch et al., AAC 2000 ; 44 : ; Schentag et al., Clin. Inf. Dis ; 32 : S39-46.
23 Which treatment for MDR-TB? Individualised or standardised treatment? Which drugs? How many drugs? Which combination? Which length for intensive phase? Which length for continuation phase? Hospitalisation or ambulatory? o No randomised clinical trial o Different results according to the setting o Expert opinions
24 PRINCIPAL WHO RECOMMENDATIONS Guidelines for the programmatic management of drug-resistant tuberculosis 2011 update. WHO/HTM/TB/2011.6
25 Composition of second-line antituberculosis regimens for MDR-TB (WHO) A fluoroquinolone should be used (strong recommendation, /very low quality evidence). A later-generation fluoroquinolone rather than an earliergeneration fluoroquinolone should be used (conditional recommendation, /very low quality evidence). Ethionamide (or prothionamide) should be used (strong recommendation, /very low quality evidence). Four second-line anti-tuberculosis drugs likely to be effective (including a parenteral agent), as well as pyrazinamide, should be included in the intensive phase (conditional recommendation, /very low quality evidence). Regimens should include at least pyrazinamide, a fluoroquinolone, a parenteral agent, ethionamide (or prothionamide), and either cycloserine or PAS (conditional recommendation, /very low quality evidence).
26 Duration of second-line anti-tuberculosis regimens for MDR-TB (WHO) An intensive phase of at least 8 months duration is recommended (conditional recommendation / very low quality evidence). A total treatment duration of at least 20 months is recommended in patients without any previous MDR-TB treatment (conditional recommendation /very low quality evidence).
27 WHO Grade evaluation system Conditional recommendation The Guideline Development Group concludes that the desirable effects of adherence to a recommendation probably outweigh the undesirable effects. Very low quality evidence ( ) Any estimate of effect is very uncertain.
28 Treatment results, cohort 2007, 44 GLC projects, 3499 MDR-TB patients Dead Lost for follow-up 15% 9% 31% No data or transferred Failure 5% Success 40% MDR WHO Progress report 2011
29 Individual data from more than 9,000 MDR-TB Lost for follow-up 23% Dead 15% 54% Success 8% Failure In Beijing, 53.4% success rate out of 716 MDR-TB cases Liu CH et al. PLoS ONE 2011;6(4): e19399
30 Alternative: 9-month treatment The Union Guide months daily Kanamycin (Km) (15 mg/kg) Gatifloxacin (400mg) (or moxifloxacin 400mg) Prothionamide(250mg) INH (10 mg/kg) Ethambutol (E) (400mg) Pyrazinamid (Z) (400mg mg) Clofazimine(50 mg) Then 5 months daily Gatifloxacin, E, Z, Clofazimine
31 9-month regimen treatment results, 206 MDR in Bangladesh (12 months after end treatment) Cured * ,5% Treatment completed** 11 5,3% Died 11 5,3% LFFU 12 5,8% Failure 1 0,5% Relapse 1 0,5% Cured = 5 negative cultures Treatment completed = culture negative at the end but less than 5 Armand Van Deun, et al. Am J Respir Crit Care Med, 2010, 182:
32 Kaplan-Meier analysis of primary adverse endpoint Probability remaining free of adverse outcome (%) Failure Default Death Relapse Gatifloxacin-based regimen Ofloxacin-based regimens 65 Hazard ratio: 0.39 (95% CI ) Ofloxacin Time in 30-day intervals Gatifloxaxin
33 Cameroon and Benin 4 Km H Gfx Pto Cfz E Z / 8 Gfx Pto Cfz E Z
34 Category of MDR-TB patients according to previous anti-tb treatment history Category Number Percentage New 0 Retreatment failure 77 67% New failure 22 19% Relapse 12 10% Other 4 3% Total / 115 were HIV positive (17%)
35 Drug resistance profile Resistant to INH and RMP only 34% Resistant to INH, RMP and SM 31% Resistant to INH, RMP and EMB 5% Resistant to INH, RMP, EMB and SM 30%
36 Sputum and culture conversion during MDR treatment 100% 80% 60% 40% Smear Culture 20% 0% Month
37 Outcomes of patients at end of treatment Outcome N=115 % Cured % Died 7 6% Failed 0 0 Defaulted 0 0 Transferred out 0 0 Among the 20 HIV+: 85% success and 15% death No relapse at one year for 55 patients
38 Niger 65 MDR-TB patients 4 KmGfxPtoCfzHEZ/8GfxCfzEZ N % Cured 58 89% Death 6 9% Failure 0 0% Default 1 2% Transfer 0 0% No relapse at one year
39 Basis of short-course chemotherapy MDR bacilli Active growth Cavities: >10 9 A Kanamycine Gati/Moxifloxacine Intermittent growth Macrophages 10 5 B Gati/Moxifloxacine Slow growth (Acid) 10 3 Dormant C Pyrazinamide Clofazimine? Moxi /GaK
40 National Drug Resistance Survey MDR-TB China, 2007 new patients: 5.7% ( ) previously treated patients: 25.6% ( ) overall: 8.3% ( ) 27.4% ( ) were fluoroquinoloneresistant MDR-TB 7.2% ( ) MDR-TB are XDR-TB WHO/HTM/TB/2010.3
41 Anti-tuberculosis drug resistance in China WHO/HTM/TB/
42 Conclusions (1) If we diagnose MDR-TB, we must cure the patients! Most of WHO recommendations for MDR-TB treatment are conditional and of very low quality evidence Still a lot of uncertainties in this field Possibly some hopes for shorter regimens (9-month), but few data, resistance to fluoroquinolones? New drugs?? Not yet available
43 Conclusion (2) If we treat MDR-TB, we must avoid development of XDR-TB Control of Second line drugs is essential Directly observed treatment is essential
44 Thank you for your attention
THE NEW DR-TB NATIONAL POLICY AND STATE OF IMPLEMENTATION
1 THE NEW DR-TB NATIONAL POLICY AND STATE OF IMPLEMENTATION Dr. Norbert Ndjeka MD, DHSM (Wits), MMed(Fam Med) (MED), Dip HIV Man (SA) Director Drug-Resistant TB, TB and HIV National Department of Health
More informationChallenges to treat MDR TB
Challenges to treat MDR TB Manfred Danilovits Tartu University Hospital, Estonian NTP Program 2nd European Advanced Course in Clinical Tuberculosis 22-24 September 2014, Amsterdam MDR-TB control; WHO Europe,
More informationDrug-resistant TB therapy: the future is now
Drug-resistant TB therapy: the future is now Gary Maartens Thanks to Francesca Conradie for sharing slides Division of Clinical Pharmacology UNIVERSITY OF CAPE TOWN IYUNIVESITHI YASEKAPA UNIVERSITEIT VAN
More informationTreatment of MDR/XDR-TB. Short course chemotherapy for MDR-TB: practical issues. CHIANG Chen-Yuan MD, MPH, DrPhilos
Treatment of MDR/XDR-TB Short course chemotherapy for MDR-TB: practical issues CHIANG Chen-Yuan MD, MPH, DrPhilos Treatment strategies for MDR-TB Standardized treatment: drug resistance survey data from
More informationMDR-TB drugs per WHO guidelines
New antituberculous agents for drug-resistant resistant TB Symposium Belgian Society of Infectiology and Clinical Microbiology November 9 Jens Van Roey, MD - Tibotec Definitions MDR-TB multidrug resistance
More informationClinical Management : DR-TB
Clinical Management : DR-TB Charoen Chuchottaworn MD., Senior Medical Advisor, Central Chest Institute of Thailand, Department of Medical Services, MoPH. Tuberculosis Classification Drug susceptible TB
More informationStrategies for Successful Treatment of Drug Resistant Tuberculosis in the U.S.
Strategies for Successful Treatment of Drug Resistant Tuberculosis in the U.S. Barbara J. Seaworth, M.D. Professor of Medicine University of Texas Health Science Center, Tyler Medical Director, Heartland
More informationTreatment of Multidrug-resistant Tuberculosis (MDR-TB)
Treatment of Multidrug-resistant Tuberculosis (MDR-TB) 2006 2008 2011 2013 2014 2016 2019 Charles L. Daley, MD National Jewish Health University of Colorado Disclosures Research grant Insmed: Phase II
More informationDR-TB PATIENT IDENTITY CARD
Ministry of Health Community Development Gender Elderly and Children National Tuberculosis and Leprosy Programme DR-TB 02 DR-TB Treatment Unit: DR-TB PATIENT IDENTITY CARD DR-TB Reg. Number: Date of registration:
More informationManagement of MDR and XDR TB Prof. Martin Boeree
Management of MDR and XDR TB 1, MD, PhD Associate Professor Consultant Respiratory Medicine Department of Lung Diseases Radboud University Nijmegen Medical Centre TB Referral Hospital Dekkerswald Nijmegen,
More informationMDR-TB is a manmade problem..it is costly, deadly, debilitating, and the biggest threat to our current TB control strategies 2
1 MDR-TB is a manmade problem..it is costly, deadly, debilitating, and the biggest threat to our current TB control strategies 2 1 India has the highest TB burden in the world 3 4 2 5 M. tuberculosis Resistance
More informationTreatment for NTM: when how.and what next? Pr Claire Andréjak Respiratory and ICU Department University hospital, Amiens, France
Treatment for NTM: when how.and what next? Pr Claire Andréjak Respiratory and ICU Department University hospital, Amiens, France First step = To diagnose NTM disease One NTM positive sample NTM disease
More informationMDR/XDR TB. Barbara Seaworth, MD, FIDSA, FACP October 27, TB Intensive October 24 27, 2017 San Antonio, TX
MDR/XDR TB Barbara Seaworth, MD, FIDSA, FACP October 27, 2017 TB Intensive October 24 27, 2017 San Antonio, TX EXCELLENCE EXPERTISE INNOVATION Barbara Seaworth, MD, FIDSA, FACP, has the following disclosures
More informationMulti-Drug and Extensively Drug Resistant Tuberculosis
Multi-Drug and Extensively Drug Resistant Tuberculosis Gwen A. Huitt, M.D., M.S. Professor, Department of Medicine Director, Adult Infectious Disease Care Unit National Jewish Health Disclosures None Tuberculosis
More informationTB Intensive Houston, Texas. Multi-Drug Resistant (MDR) TB Barbara Seaworth, MD
TB Intensive Houston, Texas November 10-12, 12 2009 Multi-Drug Resistant (MDR) TB Barbara Seaworth, MD November 12, 2009 Multi-Drug Resistant (MDR) TB Updates November 12, 2009 Barbara J. Seaworth Professor
More informationTB Intensive San Antonio, Texas
TB Intensive San Antonio, Texas April 6-8, 2011 Drug Resistant TB Barbara Seaworth, MD Thursday April 7, 2011 Barbara Seaworth, MD has the following disclosures to make: Has received research funding from
More informationTB Intensive Houston, Texas October 15-17, 2013
TB Intensive Houston, Texas October 15-17, 2013 MDR/XDR TB Barbara J. Seaworth, MD October 16, 2013 Barbara J. Seaworth, MD has the following disclosures to make: No conflict of interests No relevant financial
More informationSummary of outcomes from WHO Expert Group Meeting on Drug Susceptibility Testing - PRELIMINARY -
Summary of outcomes from WHO Expert Group Meeting on Drug Susceptibility Testing PRELIMINARY 4 th Annual GLI meeting 17 April 2012 Fuad Mirzayev Laboratories, Diagnostics and Drug Resistance unit, Stop
More informationTreatment of Drug Resistant TB
Treatment of Drug Resistant TB Diana M. Nilsen RN, MD Bureau of TB Control New York City Department of Health & Mental Hygiene Objectives Definition of other drug resistant (ODR), multiple drug resistant
More informationMultidrug resistant tuberculosis. Where next? Professor Peter D O Davies (Liverpool)
Multidrug resistant tuberculosis. Where next? Professor Peter D O Davies (Liverpool) DOTS + and LTBI New drugs for TB and the challenge of resistance talk plan 1. Epidemiology 2. Treatment 3. The MDRTB
More informationNew drugs and regimens for treatment of drug-sensitive TB (DS-TB) Patrick
New drugs and regimens for treatment of drug-sensitive TB (DS-TB) Patrick Phillips Patrick.Phillips@ucsf.edu @PPJPhillips Outline Overview of regimen development strategies 1-3 year horizon: Ongoing phase
More informationMultidrug-resistant Tuberculosis. Charles L. Daley, MD National Jewish Health Chair, Global GLC, WHO and Stop TB Partnership
Multidrug-resistant Tuberculosis Charles L. Daley, MD National Jewish Health Chair, Global GLC, WHO and Stop TB Partnership Disclosures World Health Organization Chair, Global GLC Otsuka Chair, Data Monitoring
More informationTRANSPARENCY COMMITTEE
The legally binding text is the original French version TRANSPARENCY COMMITTEE Opinion 29 October 2014 GRANUPAS, gastro-resistant granules 30 sachets with a calibrated measuring spoon (CIP: 34009 278 801
More informationTB Grand Rounds. MDR-TB: Management of Adverse Drug Reactions. Reynard J. McDonald, M.D. September 18, Patient History
TB Grand Rounds MDR-TB: Management of Adverse Drug Reactions Reynard J. McDonald, M.D. September 18, 2007 Patient History This 30 y/o H/M was born in Ecuador and immigrated to the US in 2001 On 11-22-05
More informationTB Intensive San Antonio, Texas
TB Intensive San Antonio, Texas May 6 9, 2014 MDR/XDR TB Barbara Seaworth, MD May 9, 2014 Barbara Seaworth, MD has the following disclosures to make: No conflict of interests No relevant financial relationships
More informationTB New Drugs, Shorter Courses
TB New Drugs, Shorter Courses Brian Chong John Hunter Hospital, Newcastle NSW Talk supervisor: Chris Coulter Disclosures Unfortunately none 1 Current Situation In 2013, Australia had: 1,263 notified TB
More informationSterilizing Activities of Fluoroquinolones against Rifampin-Tolerant Populations of Mycobacterium tuberculosis
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Feb. 2003, p. 653 657 Vol. 47, No. 2 0066-4804/03/$08.00 0 DOI: 10.1128/AAC.47.2.653 657.2003 Copyright 2003, American Society for Microbiology. All Rights Reserved.
More informationLinezolid: an effective, safe and cheap drug for patients failing multidrug-resistant tuberculosis treatment in India
Eur Respir J 2012; 39: 956 962 DOI: 10.1183/09031936.00076811 CopyrightßERS 2012 Linezolid: an effective, safe and cheap drug for patients failing multidrug-resistant tuberculosis treatment in India R.
More informationDrug resistant TB: The role of the laboratory
Drug resistant TB: The role of the laboratory 26 Oct 2012 Andrew Whitelaw NHSLS / UCT TB lab functions: Outline Resistance testing Genotypic Phenotypic Which tests are done when, and why Reporting of
More informationQuality of 2 nd line medicines for tuberculosis. Ms Lisa Hedman World Health Organization Department of Essential Medicines and Health Products
Quality of 2 nd line medicines for tuberculosis Ms Lisa Hedman World Health Organization Department of Essential Medicines and Health Products Case studies in medicines for tuberculosis Outline: Statistics
More informationThe New England Journal of Medicine THE TREATMENT OF MULTIDRUG-RESISTANT TUBERCULOSIS IN TURKEY
THE TREATMENT OF MULTIDRUG-RESISTANT TUBERCULOSIS IN TURKEY KEMAL TAHAOĞLU, M.D., TÜLAY TÖRÜN, M.D., TÜLIN SEVIM, M.D., GÜLIZ ATAÇ, M.D., ALTAN KIR, M.D., LEVENT KARASULU, M.D., IPEK ÖZMEN, M.D., AND NILÜFER
More informationMDR TB AND CASE STUDIES
MDR TB AND CASE STUDIES Chris Keh, MD Director, TB Prevention and Control Program, SFDPH HS Assistant Clinical Professor, Infectious Diseases, UCSF Seattle, CITC Clinical Intensive June 15, 2018 Slide
More informationPractical. Walk through New Survival Guide
Many faces of TB: Drug resistant it ttbs Survival lgid Guide v3 P B L Ch G Sh t L T P. Barry, L. Chen, G. Schecter, L. True Curry International TB Center/CTCA April 20, 2016 Real case Practical Walk through
More informationEffects of Moxifloxacin PK-PD and drug interactions on its use in the Treatment of Tuberculosis(TB)
Effects of Moxifloxacin PK-PD and drug interactions on its use in the Treatment of Tuberculosis(TB) Session: Fanning the Flames of HIV and TB Cointeraction SA AIDS Conference-Durban ICC 13-15 June 2017
More informationAntimicrobial Pharmacodynamics
Antimicrobial Pharmacodynamics November 28, 2007 George P. Allen, Pharm.D. Assistant Professor, Pharmacy Practice OSU College of Pharmacy at OHSU Objectives Become familiar with PD parameters what they
More informationUniversity of Groningen. Tuberculosis and its sequelae Akkerman, Onno
University of Groningen Tuberculosis and its sequelae Akkerman, Onno IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document
More informationExtensively Drug-Resistant Tuberculosis in South Korea: Risk Factors and Treatment Outcomes among Patients at a Tertiary Referral Hospital
MAJOR ARTICLE Extensively Drug-Resistant Tuberculosis in South Korea: Risk Factors and Treatment Outcomes among Patients at a Tertiary Referral Hospital Christie Y. Jeon, 1,2,a Soo Hee Hwang, 5,a Jin Hong
More informationPolicy guidance on drug-susceptibility testing (DST) of second-line antituberculosis drugs World Health Organization Geneva 2008
Policy guidance on drugsusceptibility testing (DST) of secondline antituberculosis drugs World Health Organization Geneva 2008 WHO/HTM/TB/2008.392 1 World Health Organization 2008 All rights reserved.
More informationThe pharmacological and microbiological basis of PK/PD : why did we need to invent PK/PD in the first place? Paul M. Tulkens
The pharmacological and microbiological basis of PK/PD : why did we need to invent PK/PD in the first place? Paul M. Tulkens Cellular and Molecular Pharmacology Unit Catholic University of Louvain, Brussels,
More informationTreatment of Nontuberculous Mycobacterial Infections (NTM)
Treatment of Nontuberculous Mycobacterial Infections (NTM) Charles L. Daley, MD National Jewish Health University of Colorado, Denver Disclosures Investigator Insmed (inhaled liposomal amikacin) Advisory
More informationIn Vitro Activities of Linezolid against Clinical Isolates of ACCEPTED
AAC Accepts, published online ahead of print on April 00 Antimicrob. Agents Chemother. doi:./aac.001-0 Copyright 00, American Society for Microbiology and/or the Listed Authors/Institutions. All Rights
More informationTitle: Resistance to fluoroquinolones and second line injectable drugs: impact on MDR TB outcomes
ERJ Express. Published on October 25, 2012 as doi: 10.1183/09031936.00134712 Title: Resistance to fluoroquinolones and second line injectable drugs: impact on MDR TB outcomes Authors: D. Falzon, N. Gandhi,
More informationMultidrug-resistant Tuberculosis
Multidrug-resistant Tuberculosis Pennan Barry, MD, MPH California MDR TB Consult Service Surveillance and Epidemiology Section Curry International Tuberculosis Center Clinical Intensive September 2016
More informationMultidrug resistant Tuberculosis
Multidrug resistant Tuberculosis Pennan Barry, MD, MPH California MDR TB Consult Service Surveillance and Epidemiology Section Curry International Tuberculosis Center Clinical Intensive October 018 Objectives
More informationSection 6.2.4: Antituberculosis Medicines Application for moving streptomycin to complementary list
Section 6.2.4: Antituberculosis Medicines Application for moving streptomycin to complementary list Stop TB Department World Health Organization Summary According to the recent guideline published in 2010
More informationThe challenge of managing extensively drug-resistant tuberculosis at a referral hospital in the state of São Paulo, Brazil: a report of three cases
J Bras Pneumol. 2015;41(6):554-559 http://dx.doi.org/10.1590/s1806-37562015000000299 CASE REPORT The challenge of managing extensively drug-resistant tuberculosis at a referral hospital in the state of
More informationXDR TB: The Laboratory s Dilemma vs The Clinician s Dilemma
XD TB: The Laboratory s Dilemma vs The Clinician s Dilemma Barbara J. Seaworth, MD, FIDSA, FACP, Heartland National TB Center, San Antonio, TX Kenneth Jost, Jr., M(ASCP) Laboratory Services Section, Texas
More informationNew antituberculosis drugs and regimens
New antituberculosis drugs: from clinical trial to programmatic use Gina Gualano, 1 Susanna Capone, 2 Alberto Matteelli, 2 Fabrizio Palmieri 1 1 Respiratory Infectious Diseases Unit, National Institute
More informationDr Sharanjit Dhoot. Chelsea and Westminster Hospital, London. 18 th Annual Conference of the British HIV Association (BHIVA)
18 th Annual Conference of the British HIV Association (BHIVA) Dr Sharanjit Dhoot Chelsea and Westminster Hospital, London 18-20 April 2012, The International Convention Centre, Birmingham 18 th Annual
More informationRisk Factors for Poor Outcomes in Patients with Multi-Drug Resistant Tuberculosis in South Korea
Hanyang Med Rev 2016;36:262-268 https://doi.org/10.7599/hmr.2016.36.4.262 pissn 1738-429X eissn 2234-4446 Original Article Risk Factors for Poor Outcomes in Patients with Multi-Drug Resistant Tuberculosis
More informationETX2514SUL (sulbactam/etx2514) for the treatment of Acinetobacter baumannii infections
ETX2514SUL (sulbactam/etx2514) for the treatment of Acinetobacter baumannii infections Robin Isaacs Chief Medical Officer, Entasis Therapeutics Dr. Isaacs is a full-time employee of Entasis Therapeutics.
More informationCase 1 and Case 2. Case 1 3/23/2016
Case 1 and Deidra D. Parrish, MD, MPH&TM Nashville Metro Public Health Dept TB Symposium March 30, 2016 Case 1 27 yo Indian woman came to the US to join her husband three months prior to clinic visit.
More informationWhich agents should we use for the treatment of multidrug-resistant Mycobacterium tuberculosis? Giovanni Di Perri* and Stefano Bonora
Journal of Antimicrobial Chemotherapy (2004) 54, 593 602 DOI: 10.1093/jac/dkh377 Advance Access publication 28 July 2004 Which agents should we use for the treatment of multidrug-resistant Mycobacterium
More informationOutline. Antimicrobial resistance. Antimicrobial resistance in gram negative bacilli. % susceptibility 7/11/2010
Multi-Drug Resistant Organisms Is Combination Therapy the Way to Go? Sutthiporn Pattharachayakul, PharmD Prince of Songkhla University, Thailand Outline Prevalence of anti-microbial resistance in Acinetobacter
More informationIntroduction to Pharmacokinetics and Pharmacodynamics
Introduction to Pharmacokinetics and Pharmacodynamics Diane M. Cappelletty, Pharm.D. Assistant Professor of Pharmacy Practice Wayne State University August, 2001 Vocabulary Clearance Renal elimination:
More informationAppropriate antimicrobial therapy in HAP: What does this mean?
Appropriate antimicrobial therapy in HAP: What does this mean? Jaehee Lee, M.D. Kyungpook National University Hospital, Korea KNUH since 1907 Presentation outline Empiric antimicrobial choice: right spectrum,
More informationDETERMINING CORRECT DOSING REGIMENS OF ANTIBIOTICS BASED ON THE THEIR BACTERICIDAL ACTIVITY*
44 DETERMINING CORRECT DOSING REGIMENS OF ANTIBIOTICS BASED ON THE THEIR BACTERICIDAL ACTIVITY* AUTHOR: Cecilia C. Maramba-Lazarte, MD, MScID University of the Philippines College of Medicine-Philippine
More informationPK/PD to fight resistance
PK/PD to fight resistance Eradicate Abnormal bacteria Mutations Efflux pumps Mutation-Preventing Concentration Breakpoint values for T > MIC and in practice With the support of Wallonie-Bruxelles-International
More informationNon-Tuberculous Mycobacterial Pulmonary Disease Diagnosis and Management Jakko van Ingen, MD, PhD
Non-Tuberculous Mycobacterial Pulmonary Disease (NTM-PD) 1 Radbound University Nihmegen Medical Center Milestones in NTM research 1980s: Nodular bronchiectatic lung disease Lady Windermere syndrome 1882-1890
More informationCLINICAL USE OF AMINOGLYCOSIDES AND FLUOROQUINOLONES
CLINICAL USE OF AMINOGLYCOSIDES AND FLUOROQUINOLONES Douglas Black, Pharm.D. Associate Professor School of Pharmacy University of Washington dblack@u.washington.edu THE AMINOGLYCOSIDES: 1944-1975 Drug
More informationJAC Bactericidal index: a new way to assess quinolone bactericidal activity in vitro
Journal of Antimicrobial Chemotherapy (1997) 39, 713 717 JAC Bactericidal index: a new way to assess quinolone bactericidal activity in vitro Ian Morrissey* Department of Biosciences, Division of Biochemistry
More informationAnimal models and PK/PD. Examples with selected antibiotics
Animal models and PK/PD PD Examples with selected antibiotics Examples of animal models Amoxicillin Amoxicillin-clavulanate Macrolides Quinolones Andes D, Craig WA. AAC 199, :375 Amoxicillin in mouse thigh
More informationJournal of Antimicrobial Chemotherapy Advance Access published August 26, 2006
Journal of Antimicrobial Chemotherapy Advance Access published August, Journal of Antimicrobial Chemotherapy doi:./jac/dkl Pharmacodynamics of moxifloxacin and levofloxacin against Streptococcus pneumoniae,
More informationDrug resistant TB: Lisa Chen, MD University of California, San Francisco Curry Interna:onal TB Center Sea=le, June 2016
Drug resistant TB: Lisa Chen, MD University of California, San Francisco Curry Interna:onal TB Center Sea=le, June 2016 Drug- Resistant TB: De1initions Mono- resistant: Resistance to a single drug Poly-
More informationOnline data supplement
Online data supplement Title: Fluoroquinolone therapy for the prevention of multi-drug resistant tuberculosis in contacts: a cost-effectiveness analysis Authors: Gregory J Fox Olivia Oxlade Dick Menzies
More informationCurrent Status of Fluoroquinolone Use for Treatment of Tuberculosis in a Tertiary Care Hospital in Korea
ORIGINAL ARTICLE https://doi.org/10.4046/trd.2017.80.2.143 ISSN: 1738-3536(Print)/2005-6184(Online) Tuberc Respir Dis 2017;80:143-152 Current Status of Fluoroquinolone Use for Treatment of Tuberculosis
More informationTb : Recent recommendation. Dr.Ketan Shah
Tb : Recent recommendation Dr.Ketan Shah Tbc : Clinician If you think It is easy to diagnose : u r not good clinician It is difficult to diagnose :U r not alone doctor to think this 6/22/2015 Ketan Shah
More informationTuberculosis in 2017: Searching for new solutions in the face of new challenges
Tuberculosis in 2017: Searching for new solutions in the face of new challenges 6th TB Symposium Ministry of Health of the Republic of Belarus, Republican Scientific and Practical Center for Pulmonology
More informationDisclosures. Principles of Antimicrobial Therapy. Obtaining an Accurate Diagnosis Obtain specimens PRIOR to initiating antimicrobials
Disclosures Principles of Antimicrobial Therapy None Lori A. Cox MSN, ACNP-BC, ACNPC, FCCM Penn State Hershey Medical Center Neuroscience Critical Care Unit Obtaining an Accurate Diagnosis Determine site
More informationDrug Resistant Tuberculosis:
Drug Resistant Tuberculosis: Pearls and other Considerations John W. Wilson, MD Associate Professor of Medicine Division of Infectious Diseases Mayo Clinic, Rochester MN Mayo Clinic Center for Tuberculosis
More informationLyme disease: diagnosis and management
National Institute for Health and Care Excellence Final Lyme disease: diagnosis and management [D] Evidence review for the management of erythema migrans NICE guideline 95 Evidence review April 2018 Final
More informationThe role of moxifloxacin in tuberculosis therapy
CLINICAL YEAR IN REVIEW TUBERCULOSIS The role of moxifloxacin in tuberculosis therapy Stephen H. Gillespie Affiliation: School of Medicine, University of St Andrews, St Andrews, UK. Correspondence: Stephen
More informationIntroduction of Bedaquiline in the Philippines
Introduction of Bedaquiline in the Philippines 24th PhilCAT Annual Convention Crown Plaza Hotel August 18,2107 Vivian S. Lofranco, MD., PHSAE National Clinical Coordinator, BDQ MDR-TB is highly contagious
More informationAlasdair P. MacGowan*, Mandy Wootton and H. Alan Holt
Journal of Antimicrobial Chemotherapy (1999) 43, 345 349 JAC The antibacterial efficacy of levofloxacin and ciprofloxacin against Pseudomonas aeruginosa assessed by combining antibiotic exposure and bacterial
More informationLong-term moxifloxacin in complicated tuberculosis patients with adverse reactions or resistance to first line drugs
Respiratory Medicine (2006) 100, 1566 1572 Long-term moxifloxacin in complicated tuberculosis patients with adverse reactions or resistance to first line drugs Luigi Ruffo Codecasa a,,1, Giovanni Ferrara
More informationWhat Have We Learned from Pharmacokinetic and Pharmacodynamic Theories?
SUPPLEMENT ARTICLE PHARMACOLOGY What Have We Learned from Pharmacokinetic and Pharmacodynamic Theories? Jerome J. Schentag, Kristin K. Gilliland, and Joseph A. Paladino State University of New York at
More informationCLINICAL USE OF AMINOGLYCOSIDES AND FLUOROQUINOLONES THE AMINOGLYCOSIDES:
CLINICAL USE OF AMINOGLYCOSIDES AND FLUOROQUINOLONES Douglas Black, Pharm.D. Associate Professor School of Pharmacy University of Washington dblack@u.washington.edu THE AMINOGLYCOSIDES: 1944-1975 Drug
More informationAdvances in Fluoroquinolones Therapy
Advances in Fluoroquinolones Therapy Fluoroquinolones Synthetic antimicrobial agents with the characteristic 4- quinolone ring structure containing a fluorine moiety at the 6-position. Some members also
More informationCHAPTER:1 THE RATIONAL USE OF ANTIBIOTICS. BY Mrs. K.SHAILAJA., M. PHARM., LECTURER DEPT OF PHARMACY PRACTICE, SRM COLLEGE OF PHARMACY
CHAPTER:1 THE RATIONAL USE OF ANTIBIOTICS BY Mrs. K.SHAILAJA., M. PHARM., LECTURER DEPT OF PHARMACY PRACTICE, SRM COLLEGE OF PHARMACY Antibiotics One of the most commonly used group of drugs In USA 23
More informationContribution of pharmacokinetic and pharmacodynamic parameters of antibiotics in the treatment of resistant bacterial infections
Contribution of pharmacokinetic and pharmacodynamic parameters of antibiotics in the treatment of resistant bacterial infections Francois JEHL Laboratory of Clinical Microbiology University Hospital Strasbourg
More informationORIGINAL ARTICLE /j x. Western Reserve University, Cleveland, OH, USA and 3 Wockhardt Research Centre, Aurangabad, India
ORIGINAL ARTICLE 10.1111/j.1469-0691.2004.01017.x Activity of the new quinolone WCK 771 against pneumococci P. C. Appelbaum 1, G. A. Pankuch 1, B. Bozdogan 1, G. Lin 1, M. R. Jacobs 2, M. V. Patel 3, S.
More informationCOMMITTEE FOR VETERINARY MEDICINAL PRODUCTS
The European Agency for the Evaluation of Medicinal Products Veterinary Medicines and Inspections EMEA/CVMP/627/01-FINAL COMMITTEE FOR VETERINARY MEDICINAL PRODUCTS GUIDELINE FOR THE DEMONSTRATION OF EFFICACY
More informationReceived 19 November 2008; returned 10 January 2009; revised 20 February 2009; accepted 24 February
Journal of Antimicrobial Chemotherapy (2009) 63, 1173 1178 doi:10.1093/jac/dkp096 Advance Access publication 28 March 2009 Fluoroquinolone resistance in Mycobacterium tuberculosis: an assessment of MGIT
More informationUpdate on Resistance and Epidemiology of Nosocomial Respiratory Pathogens in Asia. Po-Ren Hsueh. National Taiwan University Hospital
Update on Resistance and Epidemiology of Nosocomial Respiratory Pathogens in Asia Po-Ren Hsueh National Taiwan University Hospital Ventilator-associated Pneumonia Microbiological Report Sputum from a
More informationTwo-Drug Antimicrobial Chemotherapy: A Mathematical Model and Experiments with Mycobacterium marinum
Two-Drug Antimicrobial Chemotherapy: A Mathematical Model and Experiments with Mycobacterium marinum Peter Ankomah, Emory University Bruce Levin, Emory University Journal Title: PLoS Pathogens Volume:
More informationJerome J Schentag, Pharm D
Clinical Pharmacy and Optimization of Antibiotic Usage: How to Use what you have Learned in Pharmacokinetics and Pharmacodynamics of Antibiotics Jerome J Schentag, Pharm D Presented at UCL on Thursday
More informationFluoroquinolones for the treatment and prevention of multidrug-resistant tuberculosis
INT J TUBERC LUNG DIS 20(12):S42 S47 Q 2016 The Union http://dx.doi.org/10.5588/ijtld.16.0117 MDR-TB TRIALS LANDSCAPE SUPPLEMENT Fluoroquinolones for the treatment and prevention of multidrug-resistant
More informationCase Presentations: Non Responding TB Dr. Manoj Yadav
Case Presentations: Non Responding TB Dr. Manoj Yadav mbbs, dtcd, dnb (resp. dis.) Consultant Pulmonologist Kailash Hospital, Kailash Complex Near Mahadev Temple, Productivity Road Vadodara 390007 :: Phone:
More informationSystemic Antimicrobial Prophylaxis Issues
Systemic Antimicrobial Prophylaxis Issues Pierre Moine Department of Anesthesiology University of Colorado Denver 3 rd International Conference on Surgery and Anesthesia OMICs Group Conference The Surgical
More informationReceived 27 August 2002; returned 26 November 2002; revised 8 January 2003; accepted 11 January 2003
Journal of Antimicrobial Chemotherapy (2003) 51, 905 911 DOI: 10.1093/jac/dkg152 Advance Access publication 13 March 2003 AUC 0 t /MIC is a continuous index of fluoroquinolone exposure and predictive of
More informationAdvance Access published September 16, 2004
Advance Access published September 16, 2004 Journal of Antimicrobial Chemotherapy DOI: 10.1093/jac/dkh435 JAC Post-antibiotic effect induced by an antibiotic combination: influence of mode, sequence and
More informationORIGINAL INVESTIGATION. Increasing Outpatient Fluoroquinolone Exposure Before Tuberculosis Diagnosis and Impact on Culture-Negative Disease
ORIGINAL INVESTIGATION Increasing Outpatient Fluoroquinolone Exposure Before Tuberculosis Diagnosis and Impact on Culture-Negative Disease Pinky D. Gaba, MD; Connie Haley, MD, MPH; Marie R. Griffin, MD,
More informationESCMID Online Lecture Library. by author
Treatment of community-acquired meningitis including difficult to treat organisms like penicillinresistant pneumococci and guidelines (ID perspective) Stefan Zimmerli, MD Institute for Infectious Diseases
More informationTreatment of Slowly Growing NTM Infections
Treatment of Slowly Growing NTM Infections Charles L. Daley, MD National Jewish Health University of Colorado, Denver Disclosures Investigator Insmed (inhaled liposomal amikacin) Advisory Committee Insmed
More informationCreating a global community for clinical drug repurposing and development. Leonard Sacks Center for drug evaluation and research FDA
Creating a global community for clinical drug repurposing and development Leonard Sacks Center for drug evaluation and research FDA Neglected tropical diseases 1) Repurposing and developing new drugs 2)
More informationMGIT 2 nd LINE DRUG SUSCEPTIBILITY TESTING A personal experience
MGIT 2 nd LINE DRUG SUSCEPTIBILITY TESTING A personal experience Dr Johan Van Wyk MB.Ch.B, M.Med (Clin Path) Clinical Pathologist ibhayi Region, Eastern Cape GWYNETH PALTROW SHAKESPEARE IN LOVE 1998 PORT
More informationAlasdair P. MacGowan,* Chris A. Rogers, H. Alan Holt, and Karen E. Bowker
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Mar. 2003, p. 1088 1095 Vol. 47, No. 3 0066-4804/03/$08.00 0 DOI: 10.1128/AAC.47.3.1088 1095.2003 Copyright 2003, American Society for Microbiology. All Rights Reserved.
More informationOptimize Durations of Antimicrobial Therapy
Optimize Durations of Antimicrobial Therapy Evidence & Application Jill Cowper, Pharm.D. Division Infectious Diseases Pharmacist Parallon Supply Chain Solutions Richmond, VA P: 607 221 5101 jill.butterfield@parallon.com
More informationPostgraduate Course ERS Glasgow 2004 Antibiotics and the lung: pharmacokinetics
Antibiotics and the lung: pharmacokinetics Educational aims To explain the importance of pulmonary deposition of antimicrobials. To show that drugs that penetrate well and remain at the pulmonary sites
More informationAUC/MIC relationships to different endpoints of the antimicrobial effect: multiple-dose in vitro simulations with moxifloxacin and levofloxacin
Journal of Antimicrobial Chemotherapy (2002) 50, 533 539 DOI: 10.1093/jac/dkf177 AUC/MIC relationships to different endpoints of the antimicrobial effect: multiple-dose in vitro simulations with moxifloxacin
More information